Condition (MeSH)
Agenesis of Corpus Callosum
ClinicalTrials.gov lists 21 trials for Agenesis of Corpus Callosum or a narrower condition beneath it. National Human Genome Research Institute (NHGRI) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 21 trials are tagged with Agenesis of Corpus Callosum itself; the rest are tagged with a narrower condition beneath it.
When did Agenesis of Corpus Callosum trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2023 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2018 | 2 |
| 2016 | 1 |
| 2015 | 2 |
| 2012 | 1 |
| 2009 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Agenesis of Corpus Callosum trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 4 |
| Observational | 13 |
How many Agenesis of Corpus Callosum trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 12 |
| Terminated | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Agenesis of Corpus Callosum trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Human Genome Research Institute (NHGRI) | 4 |
| Gaziosmanpasa Research and Education Hospital | 1 |
| Rhythm Pharmaceuticals, Inc. | 1 |
Which drugs are being tested for Agenesis of Corpus Callosum? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Setmelanotide | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Nutropin AQ | 1 |
| Melatonin PR | 1 |
| NGS | 1 |
| Autologous tissue engineered corpora | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Agenesis of Corpus Callosum? (28)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| De novo variants in <i>SUPT16H</i> cause neurodevelopmental disorders associated with corpus callosum abnormalities. | Journal of medical genetics | 2020 | Yes |
| Haploinsufficiency of ZNF462 is associated with craniofacial anomalies, corpus callosum dysgenesis, ptosis, and developmental delay. | European journal of human genetics : EJHG | 2017 | Yes |
| The Contribution of the Corpus Callosum to Language Lateralization. | The Journal of neuroscience : the official journal of the Society for Neuroscience | 2016 | Yes |
| Clinical, genetic and imaging findings identify new causes for corpus callosum development syndromes. | Brain : a journal of neurology | 2014 | Yes |
| Autism traits in individuals with agenesis of the corpus callosum. | Journal of autism and developmental disorders | 2013 | Yes |
Showing 5 of 28 publications.
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Isolated corpus callosum agenesis | Point prevalence | Unknown | United States | US | Exact |
| Isolated corpus callosum agenesis | Prevalence at birth | 1-9 / 100 000 | United States | US | Exact |
| Isolated corpus callosum agenesis | Prevalence at birth | 1-9 / 100 000 | United States | US | Exact |
| Isolated corpus callosum agenesis | Point prevalence | Unknown | United States | US | Exact |
| Isolated corpus callosum agenesis | Point prevalence | Unknown | United States | US | Unspecified |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Isolated corpus callosum agenesis | 200 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Isolated corpus callosum agenesis | 200 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials.